BRCA2 and neoplasm: Instead, European guidelines, issued by ESMO in 2020, recommend that tissue-based molecular assays may be used in conjunction with clinicopathological factors for treatment decisions in localized prostate cancer; germline testing for BRCA2 and other DDR genes associated with cancer predisposition syndromes is recommended in patients with a family history of cancer and should be considered in all patients with metastatic PC; tumor testing for HR genes can be considered in patients with mCRPC [10].